• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于2019年全球疾病负担研究的70岁及以上成年人痛风负担变化情况

The changing burden of gout in adults aged 70 and above based on the global burden of disease 2019.

作者信息

Yang Yang, Liu Zhong

机构信息

Department of Orthopedics, Xiangtan Central Hospital, Xiangtan, China.

出版信息

Front Public Health. 2025 Feb 6;13:1455726. doi: 10.3389/fpubh.2025.1455726. eCollection 2025.

DOI:10.3389/fpubh.2025.1455726
PMID:39980931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11840442/
Abstract

INTRODUCTION

Gout is a significant global health issue, particularly among adults aged 70 and above. Understanding its epidemiological evolution and associated factors is crucial for guiding interventions and improving management.

METHODS

This study analyzed data from the Global Burden of Disease study to assess the prevalence and trends of gout among adults aged 70 and above from 1990 to 2019. We evaluated temporal trends and regional disparities by calculating the estimated annual percentage change (EAPCs).

RESULTS

Globally, the number of older adults individuals affected by gout increased from 5,316,210 cases in 1990 to 15,666,063 cases in 2019. It is noteworthy that the global burden of gout among the older adults continued to rise from 1990 to 2019, with an EAPC of 1.17 (95% CI: 1.02 to 1.32). In 2019, the prevalence rates among individuals aged 70-74, 75-79, 80-84, and 85 and above were 3,121.31 per 100,000, 3,437.17 per 100,000, 3,592.38 per 100,000, and 3,726.91 per 100,000, respectively. The regions with the highest prevalence rates of gout in 2019 were Australasia, High-income North America, and Southern Latin America, with rates of 8,500.73, 8,351.33, and 4,666.87 per 100,000, respectively. At the national level, some developed countries such as New Zealand, the United States of America, and Australia had the highest prevalence rates, reaching 8,893.74, 8,508.06, and 8,427.94 per 100,000, respectively. It is noteworthy that regions with higher levels of Socio-Demographic Index tended to have relatively higher burden of gout among the older adults, and the prevalence rates varied across different regions and age groups.

CONCLUSION

The study underscores the persistent burden of gout among the older adults, emphasizing the need for targeted interventions to address this issue and improve public health outcomes in this demographic.

摘要

引言

痛风是一个重大的全球健康问题,在70岁及以上的成年人中尤为突出。了解其流行病学演变及相关因素对于指导干预措施和改善管理至关重要。

方法

本研究分析了全球疾病负担研究的数据,以评估1990年至2019年70岁及以上成年人中痛风的患病率和趋势。我们通过计算估计的年百分比变化(EAPC)来评估时间趋势和地区差异。

结果

在全球范围内,受痛风影响的老年人数量从1990年的5316210例增加到2019年的15666063例。值得注意的是,1990年至2019年期间,老年人中痛风的全球负担持续上升,EAPC为1.17(95%CI:1.02至1.32)。2019年,70 - 74岁、75 - 79岁、80 - 84岁以及85岁及以上人群的患病率分别为每10万人3121.31例、3437.17例、3592.38例和3726.91例。2019年痛风患病率最高的地区是澳大拉西亚、高收入北美洲和拉丁美洲南部,患病率分别为每10万人8500.73例、8351.33例和4666.87例。在国家层面,一些发达国家如新西兰、美利坚合众国和澳大利亚的患病率最高,分别达到每10万人8893.74例、8508.06例和8427.94例。值得注意的是,社会人口指数较高的地区,老年人中痛风负担往往相对较高,且患病率在不同地区和年龄组之间存在差异。

结论

该研究强调了老年人中痛风负担的持续性,强调需要采取针对性干预措施来解决这一问题,并改善这一人群的公共卫生结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/625fbc8de853/fpubh-13-1455726-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/10e7d6d5c9a5/fpubh-13-1455726-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/8b8feca840d4/fpubh-13-1455726-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/49235cd5a07c/fpubh-13-1455726-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/625fbc8de853/fpubh-13-1455726-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/10e7d6d5c9a5/fpubh-13-1455726-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/8b8feca840d4/fpubh-13-1455726-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/49235cd5a07c/fpubh-13-1455726-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7446/11840442/625fbc8de853/fpubh-13-1455726-g004.jpg

相似文献

1
The changing burden of gout in adults aged 70 and above based on the global burden of disease 2019.基于2019年全球疾病负担研究的70岁及以上成年人痛风负担变化情况
Front Public Health. 2025 Feb 6;13:1455726. doi: 10.3389/fpubh.2025.1455726. eCollection 2025.
2
Global, regional, and national burden of gout in elderly 1990-2021: an analysis for the global burden of disease study 2021.全球、区域和国家老年人痛风负担 1990-2021 年:2021 年全球疾病负担研究分析。
BMC Public Health. 2024 Nov 27;24(1):3298. doi: 10.1186/s12889-024-20799-w.
3
Investigating the prevalence burden of peptic ulcer disease in older adults aged 70+ from 1990 to 2019: an analysis of Global Disease Burden Studies.1990年至2019年70岁及以上老年人消化性溃疡疾病的患病率负担调查:全球疾病负担研究分析
Eur J Gastroenterol Hepatol. 2025 Jan 1;37(1):39-46. doi: 10.1097/MEG.0000000000002847. Epub 2024 Sep 12.
4
Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease Study 2017.1990-2017 年全球 195 个国家和地区痛风的患病率、发病率及伤残调整寿命年(因痛风导致的失能)及其归因危险因素分析:基于 2017 年全球疾病负担研究的系统分析
Arthritis Rheumatol. 2020 Nov;72(11):1916-1927. doi: 10.1002/art.41404. Epub 2020 Sep 10.
5
Global, regional and national temporal trends in Parkinson's disease incidence, disability-adjusted life year rates in middle-aged and older adults: a cross-national inequality analysis and Bayesian age-period-cohort analysis based on the global burden of disease 2021.全球、区域和国家帕金森病发病率及时年趋势、中老年人群伤残调整生命年率:基于2021年全球疾病负担的跨国不平等分析和贝叶斯年龄-时期-队列分析
Neurol Sci. 2025 Apr;46(4):1647-1660. doi: 10.1007/s10072-024-07941-7. Epub 2024 Dec 14.
6
Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.1990年至2021年全球、区域和国家儿童及青少年超重和肥胖患病率及到2050年的预测:全球疾病负担研究2021的一项预测研究
Lancet. 2025 Mar 8;405(10481):785-812. doi: 10.1016/S0140-6736(25)00397-6. Epub 2025 Mar 3.
7
Burden of chronic obstructive pulmonary disease in adults aged 70 years and older, 1990-2021: Findings from the Global Burden of Disease Study 2021.1990 - 2021年70岁及以上成年人慢性阻塞性肺疾病负担:全球疾病负担研究2021的结果
PLoS One. 2025 Jan 8;20(1):e0316135. doi: 10.1371/journal.pone.0316135. eCollection 2025.
8
The global prevalence of complete hearing loss in 204 countries and territories from 1992 to 2021: a systematic analysis for the global burden of disease study 2021.1992年至2021年204个国家和地区全聋的全球患病率:全球疾病负担研究2021的系统分析
Front Public Health. 2025 Apr 9;13:1526719. doi: 10.3389/fpubh.2025.1526719. eCollection 2025.
9
Global trends in refractive disorders from 1990 to 2021: insights from the global burden of disease study and predictive modeling.1990年至2021年屈光不正疾病的全球趋势:来自全球疾病负担研究和预测模型的见解
Front Public Health. 2025 Mar 26;13:1449607. doi: 10.3389/fpubh.2025.1449607. eCollection 2025.
10
Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis.1990年至2021年10至24岁青少年和青年寻常痤疮的全球、区域和国家负担:一项趋势分析
Br J Dermatol. 2025 Jan 24;192(2):228-237. doi: 10.1093/bjd/ljae352.

本文引用的文献

1
Projections of functional dependence among the late middle-aged and older population from 2018-2048 in China: a dynamic microsimulation.2018-2048 年中国中老年人群功能依赖的预测:动态微观模拟
Glob Health Res Policy. 2024 Apr 29;9(1):15. doi: 10.1186/s41256-024-00357-y.
2
Dietary Factors and Risk of Gout: A Two-Sample Mendelian Randomization Study.饮食因素与痛风风险:一项两样本孟德尔随机化研究
Foods. 2024 Apr 21;13(8):1269. doi: 10.3390/foods13081269.
3
Optimising gout treatment: insights from a nurse-led cohort study.优化痛风治疗:一项由护士主导的队列研究的见解
RMD Open. 2024 Apr 24;10(2):e004179. doi: 10.1136/rmdopen-2024-004179.
4
Large-scale cross-ancestry genome-wide meta-analysis of serum urate.血清尿酸的大规模跨祖先全基因组荟萃分析。
Nat Commun. 2024 Apr 24;15(1):3441. doi: 10.1038/s41467-024-47805-4.
5
Pathogenesis of gout: Exploring more therapeutic target.痛风的发病机制:探索更多的治疗靶点。
Int J Rheum Dis. 2024 Apr;27(4):e15147. doi: 10.1111/1756-185X.15147.
6
Global burden of cardiovascular disease attributable to smoking, 1990-2019: an analysis of the 2019 Global Burden of Disease Study.全球归因于吸烟的心血管疾病负担,1990-2019 年:2019 年全球疾病负担研究分析。
Eur J Prev Cardiol. 2024 Jul 23;31(9):1123-1131. doi: 10.1093/eurjpc/zwae040.
7
Association between combined exposure to ambient air pollutants, genetic risk, and incident gout risk: A prospective cohort study in the UK Biobank.大气污染物暴露、遗传风险与痛风发病风险的相关性:英国生物库的前瞻性队列研究。
Semin Arthritis Rheum. 2024 Jun;66:152445. doi: 10.1016/j.semarthrit.2024.152445. Epub 2024 Mar 30.
8
Anti-gouty arthritis and anti-inflammatory effects of curcumin nanoparticles in monosodium urate crystals induced Balb/C mice.姜黄素纳米粒对尿酸单钠晶体诱导的 Balb/C 小鼠痛风性关节炎及炎症的作用。
Inflammopharmacology. 2024 Jun;32(3):1929-1940. doi: 10.1007/s10787-024-01450-x. Epub 2024 Mar 31.
9
The gout epidemic in French Polynesia: a modelling study of data from the Ma'i u'u epidemiological survey.法属波利尼西亚的痛风流行:基于 Ma'i u'u 流行病学调查数据的建模研究。
Lancet Glob Health. 2024 Apr;12(4):e685-e696. doi: 10.1016/S2214-109X(24)00012-3.
10
The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout.钠-葡萄糖共转运蛋白 2 抑制剂在痛风患者中的临床获益。
Nat Rev Rheumatol. 2024 Apr;20(4):216-231. doi: 10.1038/s41584-024-01092-x. Epub 2024 Mar 12.